<DOC>
	<DOCNO>NCT01423370</DOCNO>
	<brief_summary>The objective study assess safety efficacy oral YHD1023 5g 10g erectile dysfunction investigate optimal recommend dosage . Study period 12 week include 4weeks follow-up period without treatment . Study patient fill international index erectile function questionnaire life satisfaction questionnaire .</brief_summary>
	<brief_title>Safety Efficacy YHD1023 Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Male volunteer age 20 year old history organic erectile dysfunction least 6 month duration Anticipate adult female sexual partner , possibility pregnant breastfeed take step prevent conception study The patient legally authorize representative must sign write informed consent , prior procedure , use form approve local Institutional Review Board detail explanation purpose , content , characteristic drug Have Erectile Function ( EF ) domain score 25 result International Index Erectile Function ( IIEF ) Agree make least 4 sexual intercourse attempt 4 separate day female sexual study party 4week runin period without medication least 50 % attempts period unsuccessful due insufficient erection unable sustain penile rigidity ejaculation Have history stroke , myocardial infarction , Coronary Artery Bypass Graft surgery within last 6 month Have history cardiac failure , unstable angina , lifethreatening arrhythmia within last 6 month Shown tachyarrhythmia , heart rate 100 times/min ( e.g . arterial fibrillation , flutter ) Presence hypotension evidence SBP/DBP &lt; 90/50mmHg uncontrollable hypertension evidence SBP/DBP &gt; 170/100mmHg Presence diagnose diabetes ( HbA1C &gt; 12 % ) Have history symptomatic postural hypotension within last 6 month Have history spinal cord injury , radical prostatectomy , pelvic surgery Presence penile anatomical deformity ( e.g . severe penile fibrosis Peyronie 's disease ) Presence hypogonadism ( serum total testosterone reference low limit ) Presence hepatic impairment ( AST ALT &gt; 3 time normal upper limit ) renal impairment ( serum creatinine â‰¥ 2.5mg/dl ) Have history severe gastrointestinal hemorrhage within last 1 year Have history hematodyscrasia predispose priapism ( e.g . sickle cell disease , multiple myeloma , leukemia ) bleed disorder Subject judge ineligible accord physical checkup ( medical history , physical examination , ECG , laboratory value etc . ) within 56 day prior first administration Concomitant use one nitrates/nitric oxide ( NO ) donor ( e.g . nitroglycerine , isosorbid , mononitrate , isosorbid dinitrate , amylnitrate/nitrite , sodium nitroprusside ) , Trazodone , cancer chemotherapy , anticoagulant , androgen , antiandrogens Use PDE5 inhibitor ( e.g . Viagra , Levitra , Cialis , Yaila , Zydena ) , vasodilator selfinjection , treatment erectile dysfunction within last 2 week prior study Participated clinical trial within 30 day prior first administration Have history primary hypoactive sexual desire Subject judge ineligible principal investigator subinvestigator due mental disorder continuous drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>YHD1023</keyword>
	<keyword>YCD190</keyword>
	<keyword>Cialis</keyword>
	<keyword>Yuhan</keyword>
</DOC>